Explore the Agenda
8:00 am Check In & Light Refreshments
8:50 am Chair’s Opening Remarks
Showcasing Breakthrough Clinical Data & Assessing the Evolving Complement Landscape to Define Innovation within the Field & Strategize Future Development
9:00 am Showcasing Clinical Progress in Complement-Mediated Kidney Diseases & Generating Evidence to Advance Patient Care
- Presenting key efficacy, safety and biomarker findings from a clinical complement therapy program in kidney disease
- Evaluating treatment response across patient populations and assessing how disease biology influences clinical outcomes
- Sharing learnings from trial execution, endpoint selection and patient monitoring to inform future kidney disease development programs
NEW SPEAKING COMPANY
9:30 am Izicopan: A Best-in-Class Profile C5aR Inhibitor with Potential in ANCA Associated Vasculitis & Beyond
- Exploring the potential of C5aR inhibition to advance outcomes for patients with ANCA-associated vasculitis and other complement-mediated diseases
- Highlighting the key characteristics of a next-generation complement therapeutic and the opportunities for differentiation within an evolving treatment landscape
- Examining the future role of targeted complement inhibition across renal, inflammatory, and immune-mediated indications
10:00 am Fireside Chat: Evaluating Clinical Progress, Commercial Milestones & Emerging Opportunities to Shape the Future of Complement Therapeutics
- Reviewing the latest clinical trial readouts, approvals and pipeline developments that are redefining the complement therapeutic landscape
- Distilling lessons from recent industry headlines, strategic collaborations and development challenges to guide future innovation and portfolio decisions
- Recapping recent development and strategizing the future of complement therapeutics
10:30 am Morning Break & Speed Networking
This is your opportunity to connect with the complement community to exchange business cards, discuss your research and forge the future of drug development.
Advancing the Therapeutic Application of Complement Therapies for Indications with Unmet Need
11:30 am Antibodies, Complement, and a Durable Therapeutic Response in Oncology
- Antibodies can initiate tumor rejection
- Intra-tumoral complement activation alters the local tumor microenvironment
- Anti-tumor immunity drives a long-term clinical response
12:00 pm Early Complement-Directed Therapeutic Reprogramming of Ferroptosis- Mitochondrial & Inflammasome Signaling to Prevent Secondary Brain Injury Traumatic Brain Injury & Hemorrhagic Shock
- Elucidating the mechanistic role of early complement activation in driving ferroptosis, mitochondrial dysfunction, and inflammasome signalling that contribute to secondary brain injury following traumatic brain injury and hemorrhagic shock
- Presenting preclinical evidence that early complement-directed interventions can therapeutically reprogram interconnected cell death and inflammatory pathways, preserve mitochondrial function and cellular bioenergetics, and mitigate progressive neurological damage after trauma
- Highlighting the translational potential of complement-targeted therapies as a novel precision medicine approach to preventing secondary brain injury and improving outcomes in patients with traumatic brain injury and hemorrhagic shock
NEW SPEAKING ORGANIZATION
12:30 pm Session Reserved for Machaon Diagnostic’s
12:40 pm Lunch Break & Networking
Developing Safe, Durable & Efficacious Drugs for Neurodegenerative Diseases to Expand the Scope of Complement Therapies
1:30 pm Targeting the Terminal Pathway in Neurodegenerative Disease
NEW SPEAKING COMPANY
2:00 pm Advancing Complement Approaches to Neurodegenerative Diseases Through Innovative Delivery Strategies to Enable Treatment of CNS Indications
- Investigating the role of complement-mediated neuroinflammation in driving neuronal damage across diseases such as Alzheimer’s and Parkinson’s
- Demonstrating how modulation of complement pathways may reduce excessive synaptic pruning, neurodegeneration and chronic inflammation within the central nervous system
- Translating emerging biological insights into target selection, clinical strategies and therapeutic approaches that could improve long-term neurological outcomes
NEW SPEAKING ORGANIZATION
2:30 pm Virus-derived Immune Modulating Serpin Biologic Targets Complement to Inhibit Inflammation
- Viruses have evolved highly potent immune modulators
- Treatment with a Myxomavirus derived serpin, PEGylated Serp-1, reduces inflammation and coagulation disorders in multiple animal models
- PEGSerp-1 regulates multiple complement proteases
3:00 pm Afternoon Break & Poster Session
Share your newest research during this additional learning opportunity, and uncover the latest breakthroughs of your industry and academic peers
Harnessing the Untapped Therapeutic Potential of Complement for Ophthalmology & Other Therapeutic Areas by Optimizing Delivery, Sample Collection & Dosing
4:00 pm Intravitreal Complement Factor B Inhibition for Geographic Atrophy: RTC-4202, an Epidel®-Based Sustained-Release Implant Targeting Factor B
- Explaining the innovative way the Epidel® prodrug technology delivers drugs without polymers or delivery systems
- Introducing the rationale for an intravitreal approach to delivering Factor B inhibition locally to the retina
- Reviewing nonclinical data from the RTC-4202 IVT program demonstrating sustained PK, PD, and tolerability
NEW SPEAKING COMPANY
4:30 pm Overcoming Delivery Challenges and Role of PKPD and Translational Biomarkers in the Development of Ocular Complement Therapies
- Evaluating how novel ocular delivery approaches can overcome barriers to targeting complement pathways in retinal disease
- Leveraging PK/PD insights to optimize therapeutic exposure, dosing strategies, and clinical outcomes in ophthalmology
- Advancing complement and gene therapy approaches for AMD and other neurodegenerative eye diseases through targeted drug delivery
NEW SPEAKING COMPANY
5:00 pm Panel Discussion: Strategizing the Future of Complement Therapeutics Beyond Nephrology by Overcoming Biological, Translational & Development Bottlenecks to Treat a Plethora of Diseases
- Discussing how emerging biology and novel mechanisms are expanding the therapeutic potential of complement beyond nephrology
- Exploring solutions to delivery, target engagement and sample collection challenges in difficult-to-access tissues
- Identifying the key factors for success in new indications, including target selection, patient stratification and translational validation